NEW YORK ,
Jan. 22, 2013
/PRNewswire/ -- According to Diabetes.org, 12.6 million women in America suffer from diabetes. Type II diabetes in particular is one of the most prevalent health concerns for women, affecting 95% of those diagnosed I. Despite the statistics, the side effects for women with diabetes often go undiscussed, one in particular being sexual dysfunction.
(Photo: http://photos.prnewswire.com/prnh/20120717/NY41829 )
Although research about sexual dysfunction in women with diabetes is limited, one study found 18 percent of women with type 1 diabetes and 42 percent of women with type 2 diabetes experience sexual dysfunction.
Autonomic neuropathy, damaged blood vessel, and a reduced blood flow are often to blame and can cause decreased lubrication and vulvar dryness as well as pain or discomfort during intercourse.
There are a variety of treatment options for diabetes; however, the sexual effects are often not addressed.
To help moisturize and soothe the vulva, diabetic patients can use NeoGyn Vulvar Soothing Cream. The cream helps restore vulvar skin without estrogens
. NeoGyn relies on a scientific formulation of cutaneous lysate, a novel ingredient discovered in Switzerland after years of wound healing research
Neogyn® Vulvar Soothing Cream is a cosmetic product to help soothe and comfort the vulva.
Formulated with Cutaneous Lysate, a naturally balanced blend of proteins discovered in
, the product is non-greasy, fast absorbing and free of color additives, fragrances and analgesics. Recommended by physicians and women's health professionals, Neogyn® has a unique, patent pending blend of naturally balanced proteins that help restore well-being and comfort with twice daily use over a period of at least 6 to 8 weeks.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts